Pharvaris N.V. Ordinary Shares (PHVS)
Pharvaris N.V. is a biopharmaceutical company focused on developing therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling episodes. The company's approach involves targeting the kallikrein-kinin system to develop innovative treatments that address the underlying causes of HAE. Headquartered in the Netherlands, Pharvaris aims to improve the quality of life for patients through its pipeline of novel oral and injectable therapies.
Company News
Pharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.
Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
Within the last quarter, Pharvaris (NASDAQ:PHVS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Pharva...
Promising news from the Food and Drug Administration spurred the healthcare stock's rise.
U.S. stocks end higher on Thursday, after jobless-benefit claims rose to the highest level since February, suggesting economic growth may be slowing ahead of next week's Federal Reserve policy meeting.